

# MEDICINES NOTIFICATION

## CLASS 4 MEDICINES DEFECT INFORMATION, EL(26)A/16

### Caution In Use

Issued 26 March 2026

Distribute to Pharmacy/Wholesaler Level

#### PARELLEL IMPORT LICENCE HOLDER (PLPI)

Quadrant Pharmaceuticals Limited

#### MEDICINE DETAILS

**Vesomni 6 mg/0.4 mg modified release tablets**

PLPI 20774/2577

Active Ingredient: solifenacin succinate, tamsulosin hydrochloride

SNOMED code: 11980501000001100

GTIN: 5061052110579

#### AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
4097Y	31/12/2026	30 tablets	31/12/2025
4105Y	30/09/2026	30 tablets	31/12/2025
4322Y	31/12/2026	30 tablets	31/12/2025
5386Y	31/12/2026	30 tablets	05/01/2026
7330Y	31/12/2026	30 tablets	06/02/2026
7347Y	30/04/2027	30 tablets	12/02/2026

## Background

Quadrant Pharmaceuticals Limited have informed MHRA that their parallel imported packs of Vesomni 6 mg/0.4 mg modified release tablets have been printed with the incorrect barcode/GTIN on the carton. The GTIN printed on the affected packs is the GTIN for their parallel imported Solaraze 3% Gel 2 x 25 g packs (containing diclofenac). The other

## MEDICINES NOTIFICATION

product details on the carton, including the name, strength and pharmaceutical form of the medicine are correct. The quality of the tablets is not impacted by the labelling defect. Only the specified batches of imported packs are affected.

### Advice for Healthcare Professionals:

Do not to use this batch of medicine in robotic or automated dispensing or stocking systems. Carry out manual dispensing and stocking, as appropriate. Product quality of the Vesomni 6 mg/0.4 mg modified release tablets is not impacted by this issue, therefore the affected batches are not being recalled.

### Advice for Healthcare Professionals to Provide to Patients:

No action is needed from patients, continue to take medication from these batches of tablets. The actions will be controlled by the healthcare professionals who prescribe or dispense the medication.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

### Additional information:

For all medical information enquiries and information on this product, please email [maxearnqa@maxearn.co.uk](mailto:maxearnqa@maxearn.co.uk) or telephone 01204 471269.

For stock control enquiries please email please email [maxearnqa@maxearn.co.uk](mailto:maxearnqa@maxearn.co.uk) or telephone 01204 471269.

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

**Defective Medicines Report Centre**  
**10 South Colonnade**  
**Canary Wharf**  
**London**  
**E14 4PU**

**Telephone +44 (0)20 3080 6574**

[DMRC@mhra.gov.uk](mailto:DMRC@mhra.gov.uk)